The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Histone Deacetylase Inhibitors in Cancer Therapy
Abstract
Purpose: Epigenetic processes are implicated in cancer causation and progression. The acetylation status of histones regulates access of transcription factors to DNA and influences levels of gene expression. Histone deacetylase (HDAC) activity diminishes acetylation of histones, causing compaction of the DNA/histone complex. This compaction blocks gene transcription and inhibits differentiation, providing a rationale for developing HDAC inhibitors. Methods: In this review, we explore the biology of the HDAC enzymes, summarize the pharmacologic properties of HDAC inhibitors, and examine results of selected clinical trials. We consider the potential of these inhibitors in combination therapy with targeted drugs and with cytotoxic chemotherapy. Results: HDAC inhibitors promote growth arrest, differentiation, and apoptosis of tumor cells, with minimal effects on normal tissue. In addition to decompaction of the histone/DNA complex, HDAC inhibition also affects acetylation status and function of nonhistone proteins. HDAC inhibitors have demonstrated antitumor activity in clinical trials, and one drug of this class, vorinostat, is US Food and Drug Administration approved for the treatment of cutaneous T-cell lymphoma. Other inhibitors in advanced stages of clinical development, including depsipeptide and MGCD0103, differ from vorinostat in structure and isoenzyme specificity, and have shown activity against lymphoma, leukemia, and solid tumors. Promising preclinical activity in combination with cytotoxics, inhibitors of heat shock protein 90, and inhibitors of proteasome function have led to combination therapy trials. Conclusion: HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 4×
“Further work has identified at least 18 human HDACs, with varying function, localization, and substrates (Table 1).(16,17) The four classes of HDACs are grouped by their homology to yeast proteins.”
BackgroundInfluentialActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“In vitro and in vivo, HDAC inhibitors cause cell cycle arrest and differentiation of many tumor types, including breast cancer.(61) However, in a study of invasive breast cancer, increased HDAC1 and 3 expression was paradoxically correlated with improved disease-free survival.”
BackgroundRoth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“The function of many nonhistone proteins is also controlled by acetylation on lysine residues, and, in fact, HDACs may have appeared evolutionarily before histone-like genes.(19,20) HDACmediated deacetylation alters the transcriptional activity of nuclear transcription factors, including p53,(21) E2F,(22) c-Myc,(23) n…”
BackgroundKawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Chen, L.-F., Fischle, W., Verdin, E., & Greene, W. C. (2001) · Science · doi:10.1126/science.1062374 · Cited by 1,222
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1×
“By inducing hyperacetylation of HSP90, HDAC inhibitors disrupt the function of this critical protein chaperone that normally protects cellular and cancer-related proteins from degradation (Fig 1).(29) Affected oncogenic proteins include BCRABL, epidermal growth factor receptor, human epidermal growth factor receptor 2…”
BackgroundDuvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“A phase II trial with a similar patient population found comparable results.(93) In 13 patients who received 400 mg/d, the ORR was 31%, while 24.”
ResultA positive role for histone acetylation in transcription factor access to nucleosomal DNA
Lee, D. Y., Hayes, J. J., Pruss, D., & Wolffe, A. P. (1993) · Cell · doi:10.1016/0092-8674(93)90051-q · Cited by 1,122
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
RIGGS, M. G., WHITTAKER, R. G., NEUMANN, J. R., & INGRAM, V. M. (1977) · Nature · doi:10.1038/268462a0 · Cited by 787
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“Other cancerrelated proteins are acetylated, including the DNA repair enzyme Ku70,(28) the chaperone heat shock protein 90 (HSP90),(29) the signaling pathway intermediate STAT3,(30) and alpha-tubulin.(31)”
BackgroundRegulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
Jeppesen, P., & Turner, B. M. (1993) · Cell · doi:10.1016/0092-8674(93)90419-q · Cited by 698
Regulation of E2F1 activity by acetylation
Martínez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A., & Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.662 · Cited by 671
(1996) · Europe PMC (PubMed Central) · Cited by 659
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Histone lysine demethylases: emerging roles in development, physiology and disease
Shi, Y. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2218 · Cited by 601
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Acetylation of the C Terminus of Ku70 by CBP and PCAF Controls Bax-Mediated Apoptosis
Cohen, H. Y., Lavu, S., Bitterman, K. J., Hekking, B., Imahiyerobo, T. A., Miller, C., Frye, R., Ploegh, H., Kessler, B. M., & Sinclair, D. A. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00094-2 · Cited by 578
The Human Histone Deacetylase Family
Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 546
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
(2003) · PubMed · Cited by 519
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity
Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P. R., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 468
Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467
(2003) · PubMed · Cited by 465
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400 · cited 1×
“In addition, HDAC inhibitors decrease expression of the vascular endothelial growth factor receptor.(44) HDAC inhibition also increases generation of intracellular reactive oxygen species, and impairs handling of misfolded proteins by influencing endoplasmic reticulum stress responses.”
BackgroundByrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates
Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., Kwon, S. H., Garrido, C., Yao, T.-P., Vourc’h, C., Matthias, P., et al. (2007) · Genes & Development · doi:10.1101/gad.436407 · Cited by 368
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 366
The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60
Patel, J. H., Du, Y., Ard, P. G., Phillips, C., Carella, B., Chen, C.-J., Rakowski, C., Chatterjee, C., Lieberman, P. M., Lane, W. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10826-10834.2004 · Cited by 354
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., & Robson, C. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203423200 · Cited by 310
Structure and dynamic behavior of nucleosomes
Luger, K. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00026-1 · Cited by 300
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Histone Acetylation and Chromatin Remodeling
Gregory, P. D., Wagner, K., & Hörz, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5187 · Cited by 274
Regulation of p53 responses by post-translational modifications
Xu, Y. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401182 · Cited by 265
Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E. T., & Yu, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505585102 · Cited by 246
Zhang, C., Richon, V., Ni, X., Talpur, R., & Duvic, M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23925.x · Cited by 242
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Andtbacka, R. H. I., Dunner, K., Pal, A., Bornmann, W. G., Chiao, P. J., Huang, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2961 · Cited by 240
Maiso, P., Carvajal-Vergara, X., Ocio, E. M., López-Pérez, R., Mateo, G., Gutiérrez, N., Atadja, P., Pandiella, A., & San Miguel, J. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4186 · Cited by 238
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O’Reilly, L. A., Waterhouse, N. J., Trapani, J. A., & Johnstone, R. W. (2003) · PubMed · Cited by 233
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 228
Modesitt, S. C., Sill, M., Hoffman, J. S., & Bender, D. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.009 · Cited by 225
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 222
Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
Strevel, E. L., Ing, D. J., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6925 · Cited by 211
Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2889 · Cited by 197
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 192
Rao, R., Fiskus, W., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P., Bradner, J. E., & Bhalla, K. (2008) · Blood · doi:10.1182/blood-2008-03-143644 · Cited by 188
Crump, M., Coiffier, B., Jacobsen, E. D., Sun, L., Ricker, J. L., Xie, H., Frankel, S. R., Randolph, S. S., & Cheson, B. D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn031 · Cited by 178
Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Simms-Waldrip, T., Fu, C., & Sakamoto, K. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5989 · Cited by 174
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
Fantin, V. R., Loboda, A., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 170
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V, Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm0205-233a · Cited by 168
Blumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Development of histone deacetylase inhibitors for cancer treatment
Marchion, D. C., & Münster, P. N. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.583 · Cited by 165
Minucci, S., Nervi, C., Coco, F. L., & Pelicci, P. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204336 · Cited by 163
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas
Ishihama, K., Yamakawa, M., Semba, S., Takeda, H., Kawata, S., Kimura, S., & Kimura, W. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.029165 · Cited by 158
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Role Of Histone Phosphorylation In Chromatin Dynamics And Its Implications in Diseases
Oki, M., Aihara, H., & Ito, T. (2007) · Springer eBooks · doi:10.1007/1-4020-5466-1_14 · Cited by 142
Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy
Marks, P. A., & Jiang, X. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1564 · Cited by 142
Kummar, S., Gutierrez, M. E., Gardner, E. R., Donovan, E. A., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 140
Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Fantin, V. R., & Richon, V. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2114 · Cited by 127
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Zhang, Y., Adachi, M., Kawamura, R., & Imai, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401686 · Cited by 123
Retinoid receptors in health and disease: co-regulators and the chromatin connection
Minucci, S., & Pelicci, P. G. (1999) · Seminars in Cell and Developmental Biology · doi:10.1006/scdb.1999.0303 · Cited by 120
Rubin, E. H., Agrawal, N. G. B., Friedman, E. J., Scott, P., Mazina, K. E., Sun, L., Du, L., Ricker, J. L., Frankel, S. R., Gottesdiener, K. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1802 · Cited by 115
Ultrastructural changes in Friend erythroleukemia cells treated with dimethyl sulfoxide.
Satô, T., Friend, C., & de Harven, É. (1971) · PubMed · Cited by 113
Miyanaga, A., Gemma, A., Noro, R., Kataoka, K., Matsuda, K., 奈良, 道., Okano, T., Seike, M., Yoshimura, A., Kawakami, A., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2140 · Cited by 108
Differentiation of Erythroleukemic Cells in the Presence of Inhibitors of DNA Synthesis
Leder, A., Orkin, S. H., & Leder, P. (1975) · Science · doi:10.1126/science.1059262 · Cited by 103
Histone deacetylase inhibitors in lymphoma and solid malignancies
Rasheed, W. K., Bishton, M. J., Johnstone, R. W., & Prince, H. M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.413 · Cited by 102
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Current status of epigenetic treatment in myelodysplastic syndromes
Kuendgen, A., & Lübbert, M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0477-9 · Cited by 97
Fouladi, M., Furman, W. L., Chin, T. K., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82
Fiskus, W. C., Rao, R., Fernandez, P., Herger, B. E., Yang, Y., Chen, J., Kolhe, R. B., Mandawat, A., Wang, Y., Joshi, R., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116319 · Cited by 79
Challenges of Evaluating the Cardiac Effects of Anticancer Agents
Bates, S. E., Rosing, D. R., Fojo, T., & Piekarz, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1017 · Cited by 58
Crump, M., Glück, S., Tu, D., Stewart, D., Levine, M. N., Kirkbride, P., Dancey, J. E., O'Reilly, S., Shore, T. B., Couban, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8851 · Cited by 54
Chromatin Modification, Leukaemia and Implications for Therapy
Jones, L. K., & Saha, V. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03586.x · Cited by 51
Dejligbjerg, M., Grauslund, M., Litman, T., Collins, L. S., Qian, X., Jeffers, M., Lichenstein, H. S., Jensen, P., & Sehested, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-70 · Cited by 48
Bishton, M. J., Kenealy, M. K., Johnstone, R. W., Rasheed, W. K., & Prince, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1439 · Cited by 45
Lech‐Marańda, E., Robak, E., Korycka, A., & Robak, T. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782110178 · Cited by 26
Fischer, T. H., Patnaik, A., Bhalla, K. N., Beck, J., Morganroth, J., Laird, G., Sharma, S., Scott, J. W., Dugan, M. H., & Giles, F. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3106 · Cited by 23
Münster, P. N., Lacevic, M., Schmitt, M., Biçaku, E., Marchion, D., Stephens, A., Sullivan, L., & Minton, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3501 · Cited by 15
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Giannini, C., Hardwick, J. S., Moore, D. F., Zwiebel, J. A., & Buckner, J. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2004 · Cited by 15
Traynor, A. M., Dubey, S., Eickhoff, J. C., Kolesar, J., Marcotte, S. M., Hammes, L., Hallahan, C. M., Moore, C., Zwiebel, J. A., & Schiller, J. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.18044 · Cited by 9
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Curcumin—From Molecule to Biological Function
Esatbeyoglu, T., Huebbe, P., Ernst, I. M. A., Chin, D., Wagner, A. E., & Rimbach, G. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107724 · Cited by 904
Metadata
- Authors
- Lane, A. A., & Chabner, B. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-10
- Volume
- 27
- Issue
- 32
- Pages
- 5459-5468
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102650381
- Cited by
- 874
- References
- 126
- FWCI
- 37.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.